Co-targeting IGF-IR and c-kit: Synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells

British Journal of Cancer

Volumn 90, Issue 9, 2004, Pages 1825-1829

  Camirand, A ^a   Pollak, M ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

C kit; Co targeting; IGF IR; Small cell lung cancer; Synergy

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TYRPHOSTIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TECHNIQUE;

EID: 2642518825     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601682     Document Type: Article

References (42)

1. Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, Baserga R, Iliakis G, Aiken RD (2001) Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 19: 2189-2200
2. Arteaga CL, Kitten LI, Coronado EB, Jacobs S, Kull FC, Allred DC, Osborne CK (1989) Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84: 1418-1423
3. Berenbaum MC (1981) Criteria for analyzing interactions between biologically active agents. Cancer Res 35: 269-335
4. Camirand A, Lu Y, Pollak M (2002) Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 8: BR521-BR526
5. Chakravarti A, Loeffler JS, Dyson NJ (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200-207
6. Chun K-H, Kosmeder II JW, Sun S, Pezzuto JM, Lotan R, Hong WK, Lee H-Y (2003) Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Nat Cancer Inst 95: 291-302
7. Chute JP, Chen T, Feigal E, Simon R, Johnson BE (1999) Twenty years of phase III trials for patients with extensive-stage small cell lung cancer: perceptible progress. J Clin Oncol 17: 1794-1801
8. Dancey J, Sausville EA (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2: 296-313
9. Druker BL, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantardjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037
10. Garcia-Echeverria C, Brueggen J, Capraro H-G, Evans DB, Ferrari S, Fabbro D, Furet P, Geiger T, Liebetanz J, Marti A, Martiny-Baron G, Mestan J, Pearson MA, Ruetz S, Stolz B, Hofmann F (2003) Characterization of potent and selective kinase inhibitors of IGF-1R. Proc AACR 44: 1008
11. Heinrich MC, Blanke CD, Druker BJ, Corless CL (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20: 1692-1703
12. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen C-J, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CDM, Fletcher JA (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708-710
13. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y, Takagi H, Takahashi T (1991) Co-expression of the stem cell factor and the c-kit genes in small cell lung cancer. Oncogene 6: 2291-2296
14. Hirota S, Isozaki K, Moriyama Y, Hashimota K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal tumors. Science 279: 577-580
15. Hofmann F, Brueggen J, Capraro H-G, Cozens R, Evans DB, Fabbro D, Ferrari S, Furet P, Garcia-Echeverria C, Geiger T, Porta DG, Liebetanz J, Maira SM, Marti A, Martiny-Baron G, Mestan J, Meyer T, Ruetz S, Stoltz B, Zimmermann J, Peterson MA (2003) In vitro and in vivo profiling of selective and potent IGF-IR kinase inhibitors. Proc AACR 44: 3798
16. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21: 215-244
17. Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE, Salgia R (2002) Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-kit in small cell lung cancer cells. Cancer Res 62: 6304-6311
18. Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, Heldin CH, Waltenberger J, Bohmer FD, Levitzki A (1994) Selective platelet-derived growth factor receptor kinase blockers reverse cis-transformation. Cancer Res 54: 6106-6114
19. Krystal GW, Carlson P, Litz J (1997) Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins. Cancer Res 57: 2203-2208
20. Krystal GW, Honsawek S, Kiewlich D, Liang C, Vasile S, Sun L, McMahon G, Lipson KE (2001) Indolinone tyrosine kinase inhibitors block kit activation and growth of small cell lung cancer cells. Cancer Res 61: 3660-3668
21. Krystal GW, Honwasek S, Litz J, Buchdunger E (2000) The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6: 3319-3326
22. Krystal GW, Sulanke G, Litz J (2002) Inhibition of phosphatidyl-inositol 3-kinase Akt signaling blocks growth, promotes apoptosis and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 1: 913-922
23. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852-1857
24. Ludwig D, Burtrum D, Lu D, Anderson DM, Prewett M, Bassi R, Koo H, Jimenez X, Pereira DS, Apblett R, Kussie P, Bohlen P, Hicklin DJ, Zhu Z, Witte L (2003) A fully human monoclonal antibody to the human IGF-1 receptor that blocks ligand-dependant signaling and inhibits the growth of multiple human tumors in nude mice. Proc AACR 44: 761
25. Macaulay VM, Everard MJ, Teale JD, Trott PA, Van Wyk JJ, Smith IE, Millar JL (1990) Autocrine function for insulin-like growth factor-1 in human small cell lung cancer cell lines and fresh tumor cells. Cancer Res 50: 2511-2517
26. Melo JV (1996) The diversity of bcr-abl fusion proteins and their relationship to leukemia phenotype. Blood 88: 2375-2384
27. Micke P, Basrai M, Faldum A, Bittinger F, Ronnstrand L, Blaukat A, Beeh KM, Oesch F, Fischer B, Buhl R, Hengstler JG (2003) Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res 9: 188-194
28. Mitsiades CS, Mitsiades N, Kung AL, Garcia-Echeverria C, Pearson MA, Hofman F, Anderson KC (2003) The IGF/IGF-1R system is a major therapeutic target for multiple myeloma, other hematologic malignancies and solid tumors. Proc AACR 44: 4005
29. Moasser MM, Basso A, Averbuch SD, Rosen N (2001) The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61: 7184-7188
30. Morin MJ (2000) From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene 19: 6574-6583
31. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL (2001) Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61: 8887-8895
32. Nakanishi Y, Mulshine J, Kasprzyk P, Natale R, Maneckjee R, Avis I, Treston A, Gazdar A, Kramer B, Minna J, Cuttitta F (1988) Insulin-like growth factor-1 can mediate autocrine proliferation of human small cell lung cancer lines in vitro. J Clin Invest 82: 354-359
33. Pollak M (2000) Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36: 1224-1228
34. Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, Grimley C, Battey J, Mulshine JL, Cuttitta F (1996) Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 271: 11477-11483
35. Shawver LK, Slamon D, Ullrich A (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1: 117-123
36. Totpal K, Lewis Phillips GD, Balter I, Sliwkowski MX (2002) Augmentation of rhuMAb2C4 induced growth inhibition by Tarcevar of the EGFR tyrosine kinase on human breast cancer cell line. Proc AACR 43: 3889
37. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours : a phase I study. Lancet 358: 1421-1423
38. Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R (2000) Growth inhibition and modulation of kinase pathways of small cell lung cancer lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 19: 3521-3528
39. Wang Y, Sun Y (2002) Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. Curr Cancer Drug Targets 2: 191-207
40. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J (1995) Apoptosis induced by an anti-EGFR monoclonal antibody in human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95: 1897-1905
41. Ye D, Mendelsohn J, Fan Z (1999) Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human - mouse chimeric anti-EGF receptor mAb C225. Oncogene 18: 731-738
42. Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472-1489